AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Splenomegaly Therapeutics Market (2019-2023) to Exhibit a CAGR of Approx 3% - Analysis by Product, Type and Geography - ResearchAndMarkets.com

April 8, 2019

DUBLIN--(BUSINESS WIRE)--Apr 8, 2019--The “Global Splenomegaly Therapeutics Market 2019-2023” report has been added to ResearchAndMarkets.com’s offering.

The splenomegaly therapeutics market will register a CAGR of almost 3% by 2023.

The availability of clinical practice guidelines improves the quality of life of patients, as well as the consistency of care. There are several guidelines and care pathways for the management of splenomegaly, which have been developed by hospitals and professional societies. These are published and practiced with the aim of standardizing disease management in patients with splenomegaly.

For instance, the Hospital for Sick Children has developed a clinical practice guideline for clinicians to provide adequate disease management in children with splenomegaly. In developing countries such as India, the Association of Physicians of India published guidelines for a clinical approach for appropriate diagnosis and management of splenomegaly.

Rising awareness of splenomegaly

The incidence of splenomegaly has been seen along with many primary indications, including infections, autoimmune disorders, and hematological malignancies, which are increasing globally. Hence, the governments of various countries and several non-governmental organizations are striving to increase patient awareness about splenomegaly.

Challenges associated with diagnosis of splenomegaly

Splenomegaly is a nonspecific finding, which is challenging to assess diagnostically, as it is generally a manifestation of an underlying primary disorder. The highly advanced procedures such as point-of-care ultrasonography for the diagnosis for splenomegaly have high sensitivity compared with conventional imaging techniques. However, the poor patient access because of the high cost limits their utilization in diagnosing splenomegaly.

Competitive Landscape

The market appears to be fairly fragmented and with the presence of several vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.

Key Players

  • GlaxoSmithKline PLC
  • Incyte Corporation
  • Merck & Co. Inc.
  • Novartis AG
  • Sanofi

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: PIPELINE ANALYSIS

PART 05: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 06: FIVE FORCES ANALYSIS

PART 07: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Drug therapy - Market size and forecast 2018-2023
  • Vaccination - Market size and forecast 2018-2023
  • Market opportunity by product

PART 08: CUSTOMER LANDSCAPE

PART 09: MARKET SEGMENTATION BY TYPE

  • Congestive splenomegaly
  • Infiltrative splenomegaly
  • Neoplastic splenomegaly
  • Immune splenomegaly

PART 10: GEOGRAPHIC LANDSCAPE

  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • RoW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

PART 13: MARKET TRENDS

PART 14: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 15: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • GlaxoSmithKline PLC
  • Incyte Corporation
  • Merck & Co. Inc.
  • Novartis AG
  • Sanofi

For more information about this report visit https://www.researchandmarkets.com/r/k610g2

View source version on businesswire.com:https://www.businesswire.com/news/home/20190408005453/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Gastrointestinal Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL MANAGED CARE

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 04/08/2019 08:41 AM/DISC: 04/08/2019 08:41 AM

http://www.businesswire.com/news/home/20190408005453/en